CLEVERCARDS
8.7.2021 17:32:08 CEST | Business Wire | Press release
Giuseppe Di Marco has joined CleverCards as Senior Vice President for Business Development Europe & Managing Director of CleverCards Italia, from Accel and Battery Ventures-backed, mid-market Spend Management leader, Soldo.
Di Marco led and built the Soldo business in Italy after a successful payments career as CEO of ePay Italy (Euronet: EEFT), CEO of the Zucchetti eCommerce and payments services division (Zucchetti is Italian market leader of ERP and HR software), Managing Director of Lottomatica Payments Services Division (LIS & Totobit Servizi) and Head of QuiGroup Payments Service Division.
CleverCards is a leading global payments platform which makes it possible for anyone, anywhere, anytime, to be paid instantly by enabling businesses, governments and public sector organisations to simply send a digital prepaid Mastercard to an email address or mobile phone number by SMS or WhatsApp, empowering the recipients to spend online, or use their mobile in-store contactlessly using Google Pay, Samsung Pay or Apple Pay immediately.
“The US and European B2B payment markets are highly fragmented and CleverCards is planning to consolidate it through an aggressive buy and build acquisition strategy, driving growth and expansion through digital transformation realising its vision of becoming the ubiquitous global payments platform”, says Kealan Lennon, Founder & CEO of CleverCards.
Earlier this year, CleverCards entered into a definitive agreement to acquire ExpendiaSmart®, a market leader in Europe for Spend Management Solutions and Smart Corporate Cards, along with a Licensed, Electronic Money Institution, subject to regulatory approval.
In February this year, Mastercard and CleverCards signed a strategic partnership and development agreement to expand the usage of digital cards across Europe, a FinTech partnership that provides unprecedented, unique access to Mastercard business development teams in key markets and to key commercial clients.
“Our B2B payments platform is growing exponentially, as organisations seek to manage employee, vendor and customer pay-outs on one platform. CleverCards needed someone with an intimate understanding of the payments industry and a demonstrable ability to rapidly scale a Fintech business. In Giuseppe we’ve found that. His track record speaks for itself and we’re very excited about CleverCards continued European expansion,” adds Lennon.
At CleverCards, Giuseppe will build upon the company’s reputation as a market leader in the corporate sector with Spend Management Solutions and Smart Corporate Cards for employees, drivers and contractors, into the Public Sector with digital Mastercards, empowering social welfare recipients to spend online, or use their mobile in-store contactlessly using Google Pay, Samsung Pay or Apple Pay.
Di Marco comments, “The future of payments is digital. While many companies are scrambling to offer individual B2B solutions, none enable large private or public sector organisations to manage employee, vendor, customer or public sector payments on one platform like CleverCards. We’re providing organisations with greater speed, control and flexibility on pay-outs than ever before. I think that’s a really exciting proposition and both organisations and cardholders love it!”
ENDS
ABOUT CLEVERCARDS
Public and private sector organisations of all sizes use the CleverCards payments platform, making it possible for anyone, anywhere, anytime to be paid instantly, regardless of where they are and without the need for a bank account. Empowered with effortless configuration, customised branding and personalisation, along with elegant mobile-first cardholder experiences, CleverCards uses technology to remove numerous unnecessary processes and participants from the payments value chain, delivering unrivalled efficiencies whilst automating the management of all relevant financial services regulations, including KYC and KYB onboarding, AML and PCI DSS compliance. Since launching its payments platform in December 2019, CleverCards has experienced dramatic growth, with over 5,000 large enterprise businesses and public sector organisations already using the platform. For more information visit www.clevercards.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005694/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom